



➤ Massimo Inguglia
(DOC Sales & Marketing Manager)

Which are the benefits that the new Business Unit will bring to DOC customers and which the ones to MASCO Group?

As already anticipated by Paolo's message, the main feature of the New Business Unit can be explained looking at the final target of the new kind of services and activities that have been developed and that starting from today are part of the DOC global offer: the pharmaceutical process and the finished product. If we take a look to the DOC business core services portfolio, despite this has been constantly enriched and enlarged along the years, the scope of all these activities have been always represented by the qualification or the validation of the Pharmaceutical Equipment or Systems. With this new Business Division, DOC made several steps forwards through the enlargement of its offer to a broad kind of services in which the focus and the attention moved from the Pharmaceutical System to the Pharmaceutical Product Manufacturing (Process) or directly to the finished product and therefore to end user, the final patient. With the reference of the overview of the new activities displayed in the Company

Profile Presentation (see Download section) we are proud to announce that starting from today DOC can extend its support providing consultancy, validation and analytical activities mandatory required by Agencies for Sterile and Non sterile liquid forms Product Performance Qualification like for instance:

- Process Optimization studies
- Sterilizing filter validation or Single Use System Validation
- Endotoxin Retention Studies
- Bioburden Analysis and Process Mapping
- Sanitizing Efficacy Validation

As said above the New DOC offer to our Customers does not over here, it can continue through a set of activities developed for the characterization and the qualification of the finished product and the final container in which is filled; these activities are for instance:

- Integrity Container Closure Validation
- Final Container Material Qualification
- Toxicological Assessment and Evaluation
- Product Stability Studies
- Analytical Methods Development and Validation

In addition to all these brand new activities, the know how that stands behind them has also naturally lead to the enlargement of the kind of topics now available to be delivered, spreading our knowledge and expertise, to all our customers through training or Seminars.

Regarding instead the benefits and the advantages that this new Business Unit will bring to MASCO group, we can say that the activities described above can provide a strong benefits to Stilmas and Olsa products and their final users. Microbiological process mapping, bioburden, biofilm and contaminant characterization represent an important tool to support and qualify Stilmas Pharmaceutical Water Systems as well as process optimization and product process validation activities represent for Olsa Systems and equipment.

Events

27th May 2015

Sao Paulo (Brazil)
Hilton Hotel
Pharmaceutical water and steam systems validation as per cGMP

May 29th 2015

Curitiba (Brazil)
TECPAR - Auditorium
ALFOB - Workshop
Validação de Processos Industriais Farmacêuticos

June 4th-5th 2015

Milan (Italy)
DOC-Stilmas - Open Factory days
Production, storage and distribution of Water and Steam for pharmaceutical usage

June 15th-19th 2015

Frankfurt (Germany)
Achema Exhibition

June 23rd-24th 2015

Brussels (Belgium)
PDA Europe Conference
Quality & Regulation

